The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Helge Lund, chair of the Novo Nordisk Board, expressed confidence in the company’s strategy and its ability to execute ...

The search for a successor is currently underway. The leadership change comes as Novo Nordisk confronts recent market challenges and a decline in its share price since mid-2024. Despite the company’s ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...